EXELIXIS, INC.(EXEL)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
EXELIXIS, INC. (EXEL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EXEL at 76.2/100 on a 32-signal composite quality model, placing it at rank #87 of 2,961 stocks — the top 5% of the AI-ranked universe. EXEL scores in the top quartile across balance sheet strength (98.7), profitability (95.4), free cash flow (94.3). Shareholder dilution risk is elevated at 25.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), EXELIXIS, INC. reports quarterly revenue of $628.7M, net income of $212.1M, an operating margin of 39.5%. Top institutional holders of EXEL by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. EXEL trades on the Nasdaq exchange and files with the SEC under CIK 939767. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXELIXIS, INC. directly from SEC EDGAR.
AI Quality Score
76.2/100
AI Rank
#87
Revenue
$628.7M
Net Income
$212.1M
Free Cash Flow
$300.9M
Operating Margin
39.5%
EXEL key financials by period
EXELIXIS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.3B
$782.6M
37.6%
FY 2024
10-K
$2.2B
$521.3M
27.9%
FY 2023
10-K
$1.8B
$207.8M
9.3%
FY 2022
10-K
$1.6B
$182.3M
12.5%
FY 2021
10-K
$1.4B
$231.1M
20.0%
FY 2020
10-K
$987.5M
$111.8M
11.1%
Institutions holding EXEL
Institutional investors reporting a position in EXELIXIS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenues rose 11% to $628.7M as CABOMETYX net product revenues grew 10% to $570.6M on 6% unit growth, lifting net income to $212.1M ($0.82 diluted).
Biggest Revenue Drivers
Net product revenues$573.0M+10% YoY
6% increase in CABOMETYX units sold plus a 4% increase in average net selling price
License revenues$59.8M+21% YoY
Increases in Ipsen's net sales of cabozantinib outside the U.S. and Japan; Ipsen royalties were $50.5M
Biggest Revenue Drivers
Total revenue: $628.7M+11% YoY
Net product revenues$573.0M+10% YoY
6% increase in CABOMETYX units sold plus a 4% increase in average net selling price
Within Net product revenues
CABOMETYX$570.6M+10% YoY
Continuing demand in combination with nivolumab in first-line advanced RCC and demand in previously treated advanced NET
License revenues$59.8M+21% YoY
Increases in Ipsen's net sales of cabozantinib outside the U.S. and Japan; Ipsen royalties were $50.5M
Collaboration services revenues-$4.1M+293% YoY
Lower development cost reimbursements and higher 3% royalties paid to Royalty Pharma on partner sales
Largest Expense Items
Research and development$212.0M+6% YoY
Higher clinical trial costs for zanzalintinib, XB371 and XB628, manufacturing and license costs, offset by lower personnel expense
Selling, general and administrative$147.6M+9% YoY
Increased marketing for zanzalintinib pre-launch activities and higher personnel expenses
Cost of goods sold$20.7M+6% YoY
Higher royalties from increased U.S. CABOMETYX sales
Margins: Gross margin held at 96%, unchanged from the prior-year quarter, and management projects gross margin will not change significantly during the remainder of 2026.
Watch Items from the Filing
Generic/505(b)(2) filers MSN, Azurity, Handa, Accord and Almatica challenge CABOMETYX patents; consolidated trial set November 2, 2026, and FDA gave Handa tentative approval July 29, 2026.
Five customers each exceed 10% of revenue: McKesson 21%, Cencora 20%, CVS 15%, Accredo 10%, Cardinal Health 10%.
Zanzalintinib NDA in colorectal cancer has a PDUFA date of December 3, 2026; the NLM subgroup endpoint missed statistical significance (HR 0.83, P=0.1185).
Repurchased 20.2M shares for $902.2M under buyback programs; cash and marketable securities fell to $1.4B from $1.7B at December 31, 2025.
Future in-licensing obligations include up to $441.5M development, $278.0M regulatory and $2.5B commercial milestone payments.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
